Drug Profile
RVU 120
Alternative Names: RVU-120; SEL-120; SEL120-34; SEL120-34ALatest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Selvita
- Developer Ryvu Therapeutics
- Class Antineoplastics; Halogenated hydrocarbons; Imidazoles; Piperazines; Quinolones; Small molecules
- Mechanism of Action Cyclin dependent kinase 19 inhibitors; Cyclin-dependent kinase 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase I/II Solid tumours
- Preclinical Breast cancer; Myeloproliferative disorders
Most Recent Events
- 14 Feb 2024 Phase-II clinical trials in Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in Poland (PO) (NCT06268574)
- 14 Feb 2024 Phase-II clinical trials in Myelodysplastic syndromes (Second-line therapy or greater, Monotherapy) in Poland (PO) (NCT06268574)
- 14 Feb 2024 Ryvu Therapeutics receives clinical trial application approval from the Competent Authorities for the phase II RIVER-52 trial for Acute myeloid leukaemia (Monotherapy, Second line therapy or greater, Metastatic disease) and high-risk myelodysplastic syndrome (Monotherapy, Second line therapy or greater) in Poland and Italy, prior to February 2024